Aminoglycoside use is limited by ototoxicity and nephrotoxicity. This study compared the incidences of toxicities associated with 2 recommended dosing regimens. Eighty-seven patients with tuberculosis or nontuberculous mycobacterial infections were prospectively randomized by drug to receive 15 mg/kg per day or 25 mg/kg 3 times per week of intravenous streptomycin, kanamycin, or amikacin. Doses were adjusted to achieve target serum concentrations. The size of the dosage and the frequency of administration were not associated with the incidences of ototoxicity (hearing loss determined by audiogram), vestibular toxicity (determined by the findings of a physical examination), or nephrotoxicity (determined by elevated serum creatinine levels). Risk of ototoxicity (found in 32 [37%] of the patients) was associated with older age and with a larger cumulative dose received. Vestibular toxicity (found in 8 [9%] of the patients) usually resolved, and nephrotoxicity (found in 13 [15%] of the patients) was mild and reversible in all cases. Subjective changes in hearing or balance did not correlate with objective findings. Streptomycin, kanamycin, and amikacin can be administered either daily or 3 times weekly without affecting the likelihood of toxicity.
Streptomycin, kanamycin, and amikacin remain important drugs for treating diseases caused by Mycobacterium tuberculosis (MTB), Mycobacterium avium complex (MAC), and other nontuberculous mycobacteria (NTM) [1] [2] [3] [4] . Aminoglycosides exhibit concentrationdependent bactericidal activity, and intermittent doses overcome bacterial adaptive resistance [1, [5] [6] [7] . For gram-negative bacterial infections, larger intermittent doses of aminoglycosides have equal or greater efficacy and equal or lesser toxicity than multiple daily doses [1, 6, [8] [9] [10] . Because mycobacteria replicate at a considerably slower rate than other pathogenic bacteria, aminoglycoside treatment of mycobacterial infections has traditionally been on a daily, 3 times per week, or even 2 times per week basis [2, 3] .
Aminoglycosides may adversely affect auditory, vestibular, and renal function [1] [2] [3] . It remains unclear which parameter, if any, is most related to the development of these toxicities: the peak serum concentration (C max ), the trough serum concentration, or the total milligrams per kilogram received [1, 6, [9] [10] [11] [12] [13] . The purpose of this prospective study was to compare the incidences of toxicities among patients receiving either of 2 recommended regimens: lower aminoglycoside doses given daily (Monday through Friday) versus higher aminoglycoside doses given 3 times weekly [3, 14] . Because of the variable nature of the organisms treated, the companion drugs used, and the degree of debilitation of the patients, this study was not designed to compare the relative efficacies of these regimens.
METHODS
All eligible patients who received a diagnosis of mycobacterial disease from 1991 through 1998 at the Na- NOTE. Data are no. of patients with the specified characteristic, unless otherwise indicated. C max , maximum serum concentration back-calculated to the end of infusion; MAC, disease due to Mycobacterium avium complex; MTB, Mycobacterium tuberculosis; NTM, disease due to nontuberculous mycobacteria; t 1/2 , half-life.
tional Jewish Medical and Research Center (Denver, Colorado) were offered enrollment prospectively. Participants signed a written informed consent form that had been approved by the institutional review board of the National Jewish Medical and Research Center. Aminoglycoside selection was determined according to patient treatment history and the in vitro susceptibility of the organism (table 1) . A history and the findings of a physical examination (including data on vestibular function), audiogram findings, serum chemistry analysis, and the results of hematological testing were recorded for all patients at baseline. Patients were excluded from the study for aminoglycoside allergy, unstable renal function, estimated creatinine clearance of !30 mL/min [15] , pregnancy, or nursing.
Each aminoglycoside was randomized separately, giving a total dosage of 75 mg/kg per week. Thirty minute intravenous infusions were administered daily (15 mg/kg of ideal body weight q.d., administered Monday-Friday) or 3 times weekly (25 mg/kg t.i.w, administered Monday, Wednesday, and Friday). Audiograms were used to test bilateral hearing at 250, 500, 1000, 2000, 4000, and 8000 Hz. Two investigators performed vestibular function testing (table 2) . Initially and every 2 weeks thereafter, serum samples were obtained and aminoglycoside concentrations were determined (2 h, 6 h, and occasionally 10 h after infusion). Doses were adjusted prospectively to maintain a C max (back-calculated to the end of infusion) of 35-45 mg/mL for the daily dosing group and 65-80 mg/mL for the thrice-weekly group [16, 17] . Linear regression analyses estimated the elimination half-life (t 1/2 ), C max , and 24 h and 48 h concentrations [18] .
Serum chemistry analysis and vestibular testing results were determined weekly, and audiograms were obtained every 2 weeks for inpatients. Subjective tolerances (table 2) were determined weekly using standardized visual analogue scales (before the infusion, at the end of the infusion, and 1 h and 2h after the end of the infusion). At discharge, written monitoring instructions were sent to local physicians with requests for follow-up, and patients were provided with self-rating scales, envelopes, and mailing labels. Periodic follow-up calls and letters were sent to these individuals.
Data analysis. Primary analyses compared whether each of the 3 toxicities were present or absent during treatment and follow-up for the daily dosing group versus the thrice-weekly dosing group (for all 3 drugs combined). Nephrotoxicity was defined as an increase in the serum creatinine level of у0.5 mg/dL for patients with baseline serum creatinine levels of 0.5-1.9 mg/dL (all patients had baseline creatinines of !1.9 mg/dL) [19] . Ototoxicity was defined as a у20-db neurosensory hearing loss from baseline in either ear at any frequency [20] . Vestibular toxicity was defined as any listed test result positive for vestibular toxicity during the study. Comparisons included unpaired Student's t-test (for parametric data), and Wilcoxon rank sum and x 2 tests (for nonparametric data) (JMP software, version 5.0.1a; SAS Institute). We repeated these analyses for each drug separately, and compared additional end points (serum Dizziness at the end of follow-up 6 7 Ringing in the ears 18 18 Ringing in the ears at the end of follow-up 11 9
Subjective hearing loss 14 6 Subjective hearing loss at the end of follow-up 7 0
Tingling 10 16
Venous irritation 16 12 NOTE. Data are no. of patients, unless otherwise indicated. a One patient had 2 positive vestibular signs cations and subjective hearing and balance changes) to evaluate trends. The false-discovery rate procedure was used to control for multiple comparisons [21] . Associations between toxicities and predictor variables (i.e., drug, dose size [in mg/kg], duration of therapy, total milligrams per kilogram received, age, and sex) were determined using multivariate logistic regression (SAS software, version 8.2; SAS Institute).
RESULTS
Patient characteristics appear in table 1. Most were equally distributed between doses for each drug. By design, individual doses and C max were statistically significantly larger with thriceweekly dosing for all drugs. For streptomycin, patients in the thrice-weekly dosing group were slightly older, their median duration of therapy was somewhat longer ( ), and their P p .35 total dose in milligrams per kilogram was somewhat higher ( ). For kanamycin, patients in the thrice-weekly dosing P p .40 group were older ( ), and patients in the daily dosing P p .05 group had a somewhat longer median duration of therapy ( ) and a somewhat higher total dose ( ). For P p .37 P p .27 amikacin, patients in the daily dosing group were slightly older, and patients in the thrice-weekly dosing group had a somewhat longer median duration of therapy (
) and a somewhat P p .15 higher total dose ( ). There were 2 more patients who P p .15 had previous aminoglycoside use in the thrice-weekly dosing group than in the daily dosing group ( ). Combining P p .27 data for the 3 drugs, patients in the thrice-weekly dosing group were somewhat older (median age, 56.5 years, compared with 49 years in the daily dosing group;
). There were 47 P p .44 female patients and 40 male patients, and 25 patients had previously received aminoglycosides (10 patients in the daily dosing group and 15 patients in the thrice-weekly dosing group;
). Duration of therapy ranged from 1 to 139 weeks P p .26 (median duration, 15 weeks), and the median total dose was similar in each group (1012 mg/kg in the daily dosing group, compared with 967 mg/kg in the thrice-weekly dosing group;
). The median C max was 46 mg/mL for the daily dosing P p .86 group and 73 mg/mL for the thrice-weekly dosing group (P ! ). Most patients had 1 adjustment of their dose based on .01 serum concentrations (range, 0-5 adjustments). The median t 1/2 was 2.6 h for both groups.
Diseases were due to multidrug-resistant tuberculosis (MDR-TB) (for 18 patients in the daily dosing group and 11 patients in the thrice-weekly dosing group), MAC (for 19 patients in the daily dosing group and 29 patients in the thrice-weekly dosing group), and other NTM (for 6 patients in the daily dosing group and 4 patients in the thrice-weekly dosing group) ( ). The P p .12 daily dosing group and the thrice-weekly dosing group were balanced for the concurrent use of cefoxitin, ciprofloxacin, clofazimine, cycloserine, ethambutol, ethionamide, isoniazid, p- Ototoxicity. Ototoxicity data are shown in tables 2 and 3. Ototoxicity (defined as a hearing loss of у20 db) occurred in 32 (37%) of 87 patients. On the basis of the criterion of у15-db loss at 2 adjacent tested frequencies, 28 (32%) of the patients (14 in each group) were ototoxic [13] . Onset occurred after a median of 9 weeks of treatment in both groups (range, 2-139 weeks). Three cases occurred at 5, 15, and 32 weeks after the end of treatment, respectively; the cause is uncertain, at least in the last of these cases. Twenty-eight (88%) of the patients showed persistent changes in audiogram findings at the end of follow-up. Although high frequency hearing loss (у2000 Hz) was seen most often, 5 (16%) of the 32 patients showed deficits in both high and low frequencies. Four other patients (13%) showed deficits only in the low frequencies (250-1000 Hz). Approximately one-half of the patients lost 20-30 db, and some patients lost 35-70 db for 1 or more frequencies. Most large decibel losses were of у2000 Hz.
One ototoxic patient had serum creatinine concentrations that were greater than normal, and 6 (19%) of 32 patients were nephrotoxic (
). The size of the dose (i.e., the number P p .49 of milligrams per kilogram), the frequency of administration (daily or thrice-weekly), and the C max did not predict ototoxicity. Median C max for ototoxic patients was 55 mg/mL (range, 32-113 mg/mL), and it was 53 mg/mL (range, 26-100 mg/mL) for nontoxic patients ( ). The t 1/2 was similar in each P p .98 group (median, 2.5 h, for patients with ototoxicity; median, 2.6 h for patients without ototoxicity). All patients (except 1 ototoxic patient and 1 nonototoxic patient) had troughs of !2 mg/mL at 24 h after dosing, and all had calculated troughs at 48 h after dosing of 0 mg/mL. Ototoxicity was not associated with sex (15 female patients and 17 male patients were ototoxic), but ototoxic patients were somewhat older (median age, 56 years, compared with 48 years for nonototoxic patients;
). By multivariate logistic regression, for every 5-year P p .22 increase in age, the odds of hearing loss increased by 24% ( ; OR, 1.24; 95% CI, 1.01-1.51). Previous treatment P p .04 with aminoglycosides and concurrent treatment with clarithromycin were not associated with ototoxicity. Duration of treatment and the related total dose received were both associated with hearing loss ( for both; table 4). By multivariate P ! .01 logistic regression, for every 10-fold increase in total dose received, the odds of hearing loss increased 6.9-fold ( ; OR, P ! .01 6.87; 95% CI, 1.72-27.46). The streptomycin group had the lowest percentage of ototoxic patients (19%, compared with 42% of those receiving kanamycin and 55% of those receiving amikacin). By multivariate logistic regression, streptomycin was the least ototoxic drug (compared with amikacin, ; OR, P p .03 0.25; 95% CI, 0.07-0.89). Given the severity of some of the infections treated (or the extent of resistance to alternative drugs), treatment continued in many cases despite toxicity.
Ototoxicity did not correlate with vestibular toxicity on physical examination or with subjective hearing or balance changes reported by the patients. Subjective hearing changes (in 20 patients) occurred a median of 2 weeks into treatment (range, 1-12 weeks) and lasted 2-3 weeks (range, 1-15 weeks). Only 8 of 20 patients with subjective hearing changes ( ) and P p .77 15 of 36 patients with ringing in the ears ( ) had mea-P p .59 surable changes on an audiogram. Most subjective hearing changes were mild and appeared to be infusion-related: they were negative at baseline, increased after dosing, and were negative again at the next baseline. A few changes were rated moderate or pronounced, yet most resolved over time.
Vestibular toxicity. Eight (9%) of 87 patients (4 from the daily dosing group and 4 from the thrice-weekly dosing group) had у1 positive vestibular sign on у1 occasion; the rate for any single positive finding was 3%. Most changes lasted 1-2 weeks, and all occurred within the first 6 weeks of dosing. Five female patients and 3 male patients, aged 34-79 years (median age, 59 years), were affected. One patient (receiving a thriceweekly dose of streptomycin) had both nystagmus and heelto-toe walking changes. For 2 patients (aged 64 and 79 years), aminoglycoside therapy was stopped, and the last available vestibular test results were positive (there was no long-term follow-up). No patient with positive vestibular signs had received earlier treatment with aminoglycosides ( ), 3 of the 8 P p .07 patients also had hearing loss ( ), and 1 of the 8 patients P p .86 was also nephrotoxic ( ). The median C max was 52 mg/ P p .82 mL (range, 47-81 mg/mL) for patients with vestibulotoxicity and 54 mg/mL (range, 26-113 mg/mL) for patients without it (
). There were no statistical relationships between ves-P p .92 tibular toxicity and the other parameters.
Subjective measures of vestibular toxicity were more common. Subjective balance changes occurred in 36 (41%) of the patients (28 of whom were female) (median age, 62 years, compared with 48 years for patients without balance changes). Likewise, dizziness was noted by 41 (47%) of the patients (26 of whom were female) (median age, 58 years, compared with 50 years for those without dizziness). The median duration of treatment was similar for those with and those without these symptoms (15 weeks for both groups). Most subjective balance changes were rated as mild, and most appeared to be infusionrelated. A few were rated moderate or pronounced, but the majority resolved over time.
Nephrotoxicity. Nephrotoxicity was mild and short lived. Thirteen (15%) of 87 patients were nephrotoxic (tables 2 and 3). Only 4 patients had serum creatinine concentrations that increased above normal levels (11.2 mg/dL), despite the increase of у0.5 mg/dL. One nephrotoxic patient from the thriceweekly dosing group had elevated serum creatinine levels before and after treatment. One questionable case occurred 4 weeks after amikacin therapy was discontinued, and 1 patient developed nephrotoxicity 1 week after receiving kanamycin, following a full week of treatment with amphotericin B. Nephrotoxicity lasted a median of 1 week (maximum duration, 12 weeks), and all cases resolved without sequelae. The size of the dosage, frequency of dosing, duration of therapy, total dose received, and C max did not predict nephrotoxicity. The median C max was 66 mg/mL (range, 33-103 mg/mL) for nephrotoxic patients and 53 mg/mL (range, 26-113 mg/mL) for nontoxic patients (P p ). The t 1/2 was similar for both groups (median for patients .45 with nephrotoxicity, 2.9 h; median for patients without nephrotoxicity, 2.5;
). All nephrotoxic patients had trough P p .67 levels of !2 mg/mL at 24 h after dosing, and all of the patients had calculated trough levels at 48 h after dosing of 0 mg/mL.
Nephrotoxicity was not associated with sex, although patients with nephrotoxicity were somewhat older (median age, 59 years) than those without it (median age, 52 years;
). Previous P p .55 use of aminoglycosides was not associated statistically with nephrotoxicity (38% of those with nephrotoxicity and 27% of those without it had previously used aminoglycosides;
). The P p .42 one patient with prior renal disease did not become nephrotoxic; none of the 3 patients receiving cefoxitin, none of the 4 patients receiving furosemide, and 1 of the 6 patients receiving a daily dose of an NSAID ( ) developed nephrotoxicity. The P p .90 kanamycin group had the lowest percentage of nephrotoxic patients (9%, compared with 19% each for the streptomycin and amikacin groups). By multivariate logistic regression, the order of nephrotoxicity, by drug received, was streptomycin, followed by amikacin, followed by kanamycin (streptomycin vs. kanamycin,
). There were no statistical associations between P ! .05 nephrotoxicity and ototoxicity, vestibular toxicity, or the subjective balance or hearing changes.
Serum cation changes generally were short lived. Mild hypocalcemia occurred at 4-22 weeks of therapy and lasted 1 week (no nephrotoxic patients experienced hypocalcemia). Mild hypokalemia occurred at 1-26 weeks of therapy and lasted р4 weeks (median duration, 1 week), and those who experienced hypokalemia included 5 nephrotoxic patients. Mild hypomagnesemia occurred at 1-28 weeks of therapy and lasted р8 weeks (median duration, 2 weeks), and those who experienced hypomagnesemia included 5 nephrotoxic patients. No patient had reductions in all 3 cations, and there were no apparent ill effects. Although some cation differences reached statistical significance, after controlling for multiple comparisons, no secondary analyses were statistically significant. Overall, there were no significant differences in any toxicity between the daily and thrice-weekly doses for the 3 drugs combined, or between the daily and thriceweekly doses for each drug individually.
DISCUSSION
Our patients had advanced MDR-TB or complicated NTM infections, and most patients received long courses of aminoglycosides. This unique population allowed us to compare the toxicities of 2 recommended regimens for streptomycin, kanamycin, and amikacin concurrently over extended periods [14] . To our knowledge, no such direct comparison of safety has been done previously.
Ototoxicity (i.e., hearing loss) was not associated with the size or frequency of the aminoglycoside dosage, but it was associated with older age, longer duration of treatment, and greater total dose received. Ototoxicity occurred independently of nephrotoxicity or vestibular toxicity. Vestibular toxicity was uncommon and showed variable manifestations, any one of which was even less common. It could not be predicted on the basis of any patient characteristics, including the size or frequency of the aminoglycoside dosage. Detection remains challenging, as there is no vestibular monitoring protocol with documented efficacy, reliability, and suitability for patients who are ill [22] .
Subjective changes in balance or hearing were more common than objective changes, but they, too, were not predictable. Fortunately, most changes were mild and reversible, and they often seemed to be related temporally to the infusion of the drug, rather than to be a persistent finding. Slowing the rate of infusion from 30 min to 60 min seemed to help selected patients. Two mechanisms have been proposed for hearing loss, and 1 mechanism (competition with calcium) is readily reversible [12] . Subjective hearing loss may be a better measure of that change than the destruction of hair cells within the cochlea [12] .
Nephrotoxicity was not associated with any patient characteristics or the size and frequency of aminoglycoside dosage. Although nephrotoxicity could not be predicted, it was mild and reversible in all cases. Streptomycin, considered to be the least nephrotoxic of these drugs on the basis of animal models, was associated with more than one-half of these events [3, 12, 23] . Streptomycin, considered to be more ototoxic than the other drugs, was associated with only 6 of 32 hearing loss events [3, 12, [24] [25] [26] . Therefore, previously described tendencies for selected toxicities were not seen with our patient population. Historically, streptomycin was dosed daily or thrice weekly for many months in patients with chronic MTB [2, 3] . In contrast, kanamycin and amikacin were dosed every 8-12 h in patients with acute gram-negative bacterial infections [1] . Therefore, perceived differences in toxicities among these 3 aminoglycosides may reflect widely differing clinical uses. With identical dosing schemes and similar durations of treatment, streptomycin, kanamycin, and amikacin showed similar, although not identical, patterns of toxicity.
All patients were treated with multiple drugs, so it is a possibility that the adverse events were caused by another drug or by synergistic effects with another drug. Cefoxitin, furosemide, and NSAID use did not affect the incidence of nephrotoxicity, and clarithromycin use did not affect the incidence of ototoxicity [27] . We did not address potential genetic predispositions to these toxicities [1, 28, 29] . Other limitations included variable durations of follow-up and more detailed follow-up from some local physicians than from others. These variables appeared evenly distributed between dosing groups.
The pharmacokinetics of streptomycin, kanamycin, and amikacin were nearly identical, and target concentrations were achieved routinely through the use of serum concentration monitoring and dose adjustment [16, 17] . Streptomycin recipients were somewhat older than other subjects, and the t 1/2 for these patients was somewhat longer than for the kanamycin and amikacin recipients. This appeared to be consistent with known age-related decreases in renal function [1, 15] .
We propose that the size and frequency of the aminoglycoside dosage be based on logistical considerations and the desired ratio of C max to MIC. Given concentration-dependent killing, aminoglycoside dosing 3 times per week might be advantageous for slow-growing mycobacteria with MICs of у4 mg/mL [1, 5, 6] .
Our data do not support the 2003 American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC), and Infectious Disease Society of America (IDSA) recommendation for lower doses in older patients [3] . Hearing loss was more prevalent among older patients, but was not associated with dose, frequency, or C max . Lowering the dose lowers the C max / MIC ratio and could reduce efficacy. In turn, lower doses could prolong the duration of aminoglycoside use, thus increasing the risk of ototoxicity. We recommend that full doses be used for the shortest durations possible in older patients. Furthermore, we recommend objective testing during follow-up, given the lack of correlation between subjective and objective measures of hearing loss or vestibular toxicity.
Our data do not support the 2003 recommendations of the ATS/CDC/IDSA regarding "maximum" aminoglycoside doses. Capping the doses at 1000 mg could lead to underdosing large patients. For example, a dosage of 15 mg/kg daily for a 190-cm (6-foot, 4-inch) male patient weighing 190 pounds (87 kg; i.e., ideal body weight) gives a total dose of 1300 mg, rather than 1000 mg (i.e., 11.5 mg/kg). Note that "single daily dose" aminoglycoside therapy for gram-negative bacterial infections uses standard milligram-per-kilogram doses without an arbitrary maximum (range, 5-10 mg/kg). "Maximum doses" will not lower the risks for toxicities directly but could reduce efficacy, prolong treatment, and increase the risk of hearing loss.
Our findings are in general agreement with those of Fee [30] , who studied gentamicin and tobramycin. Fee noted "the probable multivariable nature of human ototoxicity" [30, pg. 2] and the general lack of consistent predictors for either hearing loss or vestibular damage. Hawkins [31] summarized the history of drug ototoxicity and noted that attempts to minimize aminoglycoside-induced ototoxicity, including alternative salt forms of the drugs, have not been particularly successful. A recent retrospective chart review from The Netherlands [32] showed somewhat different results from those presented here. In that study [32] , most patients received kanamycin for a median of 12 weeks. Initially, aminoglycosides were given daily, and they were then switched at variable intervals to 3-5 doses per week. Nephrotoxicity (but not ototoxicity) was associated with longer durations of treatment. Differences in patient populations and methodology precluded further direct comparisons with our data. In both studies, longer durations of treatment were associated with selected toxicities, and most toxicities could not be predicted on the basis of patient characteristics.
In conclusion, our data suggest that streptomycin, kanamycin, and amikacin can be dosed at either 15 mg/kg q.d. (administered Monday-Friday) or 25 mg/kg t.i.w., depending on the clinical situation, without affecting the likelihood of toxicity. Should the isolate be susceptible to all 3 drugs, streptomycin appears to be the least likely to cause hearing loss, a frequently irreversible adverse effect. Clinicians should remain vigilant regarding potential aminoglycoside-associated toxicities, even with shorter courses of treatment. Older patients should be given the shortest possible courses of treatment but should not receive smaller-than-usual dosages. Large patients should receive the appropriate milligram per kilogram dosage, determined on the basis of ideal body weight, even if the dosage exceeds 1000 mg.
